ARTICLE | Emerging Company Profile
SciNeuro reunites GSK R&D vets to bring CNS therapies to China
Emerging Company Profile: SciNeuro to build neurodegeneration, neuropsychiatric pipeline via partnering, in-house R&D
January 22, 2021 1:19 AM UTC
Led by GSK neuro R&D alumni and fueled by $100 million in series A funds, SciNeuro aims to develop neurodegeneration and neuropsychiatric therapies for the Greater China market through a mix of partnering and in-house R&D.
SciNeuro Pharmaceuticals Ltd. emerged from stealth in December, three years after GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) announced the closing of its Shanghai neuroscience R&D center and relocation of key programs to its global R&D hub in Upper Providence Township, Pa. The newco has headquarters in both Shanghai and Philadelphia...